Ontvang nu dagelijks onze kooptips!

word abonnee
Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee

  • Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Markt vandaag Koersen Forum Premium IEX Expert
Home  /  Forum  /  Crucell  /  crucell dinsdag 20 januari , vandaag gaat het gebeuren

Crucell« Terug naar discussie overzicht

crucell dinsdag 20 januari , vandaag gaat het gebeuren

Volgen
51 Posts
Pagina: «« 1 2 3 »» | Laatste | Omlaag ↓
  2. B_B 20 januari 2009 15:04
    Bij huidige beursklimaat zal Crucell als 1 van de weinige aandelen niet veel dalen.
    Dus of cash of Crucell.

    Een bod van Wyeth komt zeker.
    Uiteindelijk wordt Novartis (met een tegenbod)de nieuwe eigenaar van Crucell.

    Wyeth's Multibillion-dollar Biotech Bet
    By: Elizabeth SvobodaThu Jan 15, 2009 at 6:26 PM

    Drugmaker Wyeth bet billions on biotech, transforming its culture and boosting profits.

    It seemed like a disaster. In July, Wyeth BioPharma -- which everyone, inside the company and out, calls Wyeth Biotech -- released clinical results showing that its much-touted Alzheimer's drug, bapineuzumab, had failed to meet expectations. Papers screamed with headlines like Wyeth May Be Dead Money After Alzheimer's Setback. Some analysts raised doubts that the drug, which had been seen as a potential blockbuster, could get FDA approval. Its parent company's share price dropped more than 10% in a day.

    Yet the mood at Wyeth Biotech's Andover, Massachusetts, research campus remained upbeat, the vibe more rah-rah startup than uptight, market-obsessed Big Pharma. Huge gambles and the constant possibility of failure are integral to the unit, the product of an unconventional decade-long experiment at its parent, pharma giant Wyeth Pharmaceuticals. Most pharmaceutical companies steered clear of biotech back when its methodology -- cultivating living cells and using them to churn out complex, large-molecule drugs -- was still being perfected. But Wyeth took a big risk. In the 1990s, it acquired two of the country's most promising biotech companies, Genetics Institute and American Cyanimid. Over the following years, it combined them into Wyeth Biotech and spent more than $3.5 billion to grow them.

    The result has been a rich symbiotic exchange. Fed by the resources of its parent, Wyeth Biotech has blossomed. And the upstart unit has changed Big Wyeth, too, persuading managers to emulate its ambitious approach and rewarding employees not for showing up but for performance. It has also produced some of Wyeth's best-known, most-lucrative drugs, including the pneumococcal vaccine Prevnar ($2 billion in revenue per year) and rheumatoid-arthritis injection Enbrel ($3.5 billion). Even with disappointment over bapineuzumab, there are scores of biotech products in the pipeline, from anti-inflammatory drugs to treatments for cancer, and "40% to 45% of our revenues now come from biotech," says Mike Kamarck, Wyeth's president of technical operations and product supply. "In a year or two, it'll be more than half." Wyeth as a whole is performing well despite challenging market conditions. Profits have risen 12% in the past two years. In July, the company hiked its earnings guidance for 2008, and in October, it confirmed it was on target to make those numbers.

    Perhaps the best measure of Wyeth's biotech success is that other Big Pharma companies are now trying to follow suit. In October, Eli Lilly won a bidding war with Bristol-Myers Squibb for ImClone, a prominent biotech company with several cancer drugs in its pipeline, with an offer of $6.5 billion. In July, Roche made a gargantuan $44 billion bid to gain full ownership of biotech leader Genentech, in which it had a partial stake. And GlaxoSmithKline announced that it would focus more on growth areas like biotech. But in a Credit Suisse report issued last fall, research analyst Catherine Arnold gave Wyeth an edge, calling it "one of the most attractive targets in the global pharmaceutical space" and citing the strength of the company's biologics products as well as its research pipeline.

    Wyeth's biotech focus was born of uncertainty within the company. In 2002, a government-sponsored trial of one of Wyeth's flagship products, Prempro -- a drug designed to relieve menopausal symptoms -- ended prematurely for safety reasons. "It was one of our biggest products," Kamarck says, "and it had its legs taken out from under it."

    Amid the turmoil, Bernard Poussot, then president of Wyeth's pharmaceutical division and now CEO of the entire company, pondered the firm's biotech gamble -- and decided to double down. He felt that large-molecule drugs, which can be endlessly customized, would eventually transform the industry. "The small-molecule world was shrinking in terms of innovation," Poussot says. "With large molecules, you can be a lot more specific in your treatment approach -- you can correct a lot of deviations at the cell level."

    But when Poussot floated his biotech hunch in meetings with senior management, he met resistance. "The question was, 'Can we actually do this?' " Kamarck says.

    Poussot parried the naysayers with a vehement "Yes!" and an unprecedented gambit. In 2003, to build the company's biotech focus, he created a new business unit devoted to marketing Wyeth Biotech's products -- a move meant to send a message about the future of the company as a whole. The biotech-business culture that had fostered so much innovation needed to be allowed to flourish. "It's almost like academia," says biotech-project specialist Lisa Housiantis. "You're given the freedom to try out your ideas."

    Cash (Kept at Home) Is King
    By JOHN JANNARONE and SARA SILVER

    Cash on U.S. balance sheets was once a juicy target for activist investors. Now it is a source of comfort for those seeking security in the stock-market rout.

    But is cash always liquid? And are cash-rich balance sheets really as powerful as they seem?

    Take the pharmaceutical and technology industries. Between them they include some of the world's biggest companies with ultra-secure balance sheets. At the end of September, U.S. tech companies had total cash and short-term investments of $260 billion, compared with debt of $220 billion, according to Fitch Ratings.

    Nine of the largest pharmaceutical companies, meanwhile, had a combined $113 billion in cash and investments versus $83 billion of debt, according to Moody's.

    But a large proportion of that is parked overseas and can't be brought home without paying an extra tax charge of as much as 30%. That can make a big difference. Some large pharmaceutical firms hold as much as 75% of their cash abroad, according to Moody's. Since overseas cash piles can't be brought home without a penalty, the ratings provider applies a discount in its analysis. Pfizer's $34.4 billion in cash and investments gets a 30% haircut, as does Johnson & Johnson's $14.8 billion.

    For cash-rich companies, it is an annoyance. Even with all those reserves, J&J had to issue debt last year to make dividend payments because so much is held abroad, according to Moody's. Meanwhile, those who want to take advantage of the current market turmoil to buy rivals might find themselves pushed toward overseas deals if they want to use cash. Moody's reckons Wyeth has at least half its $14.2 billion in gross cash and investments overseas -- allowing it to pay the expected $1.5 billion bill for Dutch vaccine maker Crucell without paying extra U.S. tax.

    For weaker companies foreign cash can be a bigger problem. Motorola Inc. estimates 90% of its $7.6 billion cash pile is held overseas. That creates a potential headache, as its mobile-devices unit bleeds cash and the company has to service its $4.2 billion of debt, all in the U.S. The telecom-equipment maker is looking for ways to repatriate cash. In its
  6. forum rang 8 josti5 20 januari 2009 17:43
    quote:

    lafite rothschild schreef:

    16,85?? Is de koers losgelaten?
    Haha, da's nog maar de vraag...

    Mijn inschatting:

    *Of Crucell is bedolven onder de mails, vandaar dat men besloten heeft een standaard-antwoord terug te sturen en de koers een tikkie los te laten
    *Of de koers mag wat losser op basis van de voortgang van de overnamebesprekingen.

    Wat mij betreft: kans 20/80.
  13. Dennis V. 20 januari 2009 19:23
    Zoals reeds Crucell zelf heeft aangegeven, zal er in ieder geval een mededeling komen, indien er iets concreets naar de aandeelhouders toe, te melden valt.
    Bij de eerste melding in de eerste week van januari had Crucell het over "friendly talks".
    Persoonlijk denk ik, dat er in week van 26 januari a.s. meer duidelijkheid in de zaak komt.
  14. forum rang 4 harvester 20 januari 2009 19:43
    quote:

    Dennis V. schreef:

    Zoals reeds Crucell zelf heeft aangegeven, zal er in ieder geval een mededeling komen, indien er iets concreets naar de aandeelhouders toe, te melden valt.
    Bij de eerste melding in de eerste week van januari had Crucell het over "friendly talks".
    Persoonlijk denk ik, dat er in week van 26 januari a.s. meer duidelijkheid in de zaak komt.

    waarom?? waarover??
  18. [verwijderd] 20 januari 2009 20:38
    quote:

    Dennis V. schreef:

    Zoals reeds Crucell zelf heeft aangegeven, zal er in ieder geval een mededeling komen, indien er iets concreets naar de aandeelhouders toe, te melden valt.
    Bij de eerste melding in de eerste week van januari had Crucell het over "friendly talks".
    Persoonlijk denk ik, dat er in week van 26 januari a.s. meer duidelijkheid in de zaak komt.

    Dan is het zaak om de cijfers van Q4 en de nieuw af te geven outlook met kritische ogen te bekijken.

    ;-)
  19. forum rang 8 josti5 20 januari 2009 20:44
    quote:

    Achzonder schreef:

    [quote=Dennis V.]
    Zoals reeds Crucell zelf heeft aangegeven, zal er in ieder geval een mededeling komen, indien er iets concreets naar de aandeelhouders toe, te melden valt.
    Bij de eerste melding in de eerste week van januari had Crucell het over "friendly talks".
    Persoonlijk denk ik, dat er in week van 26 januari a.s. meer duidelijkheid in de zaak komt.

    [/quote]

    Dan is het zaak om de cijfers van Q4 en de nieuw af te geven outlook met kritische ogen te bekijken.

    ;-)
    Yep: zoals het er nu naar uit ziet, gaan de boel besodemieterd worden: alle shit eruit, en een zwarte toekomst tegemoet...
51 Posts
Pagina: «« 1 2 3 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Markt Vandaag

Stijgers

instrument koers absoluut verschil relatief verschil
Kendrion 13,200 +0,54 +4,27%
JDE PEET'S 21,120 +0,68 +3,33%
Aegon 5,534 +0,18 +3,32%
AZERION 1,460 +0,05 +3,25%
Accsys 0,651 +0,02 +3,17%
ASR Nederland 44,510 +1,12 +2,58%
Sif Holding 12,600 +0,30 +2,44%
FASTNED 16,000 +0,38 +2,43%
PostNL 1,249 +0,03 +2,29%
Air France-KLM 8,258 +0,17 +2,15%
SIGNIFY NV 21,580 +0,44 +2,08%
EBUSCO HOLDING 1,010 +0,02 +1,92%
CTP 16,480 +0,28 +1,73%
Aperam 24,200 +0,40 +1,68%
JUST EAT TAKEAWAY 12,815 +0,19 +1,50%
Flow Traders 17,690 +0,26 +1,49%
NN Group 44,960 +0,66 +1,49%
ABN AMRO BANK N.V. 15,510 +0,22 +1,44%
RANDSTAD NV 43,490 +0,60 +1,40%
KPN 3,733 +0,05 +1,30%
ArcelorMittal 20,280 +0,26 +1,30%
TomTom 5,110 +0,07 +1,29%
NSI 20,400 +0,25 +1,24%
Vopak 42,060 +0,50 +1,20%
Basic-Fit 22,400 +0,26 +1,17%
ING 16,262 +0,18 +1,11%
Corbion 23,760 +0,26 +1,11%
Eurocommercial Properties 24,100 +0,25 +1,05%
Akzo Nobel 57,980 +0,58 +1,01%
Van Lanschot Kempen NV 40,850 +0,35 +0,86%
AMG Critical Materials N.V. 14,230 +0,12 +0,85%
WDP 24,360 +0,20 +0,83%
ForFarmers 3,160 +0,03 +0,80%
B&S Group SA 4,655 +0,04 +0,76%
Philips Koninklijke 27,210 +0,20 +0,74%
Heineken 82,080 +0,58 +0,71%
Wereldhave 14,320 +0,10 +0,70%
ALLFUNDS GROUP 5,240 +0,04 +0,67%
CM.COM 6,340 +0,04 +0,63%
PROSUS 33,515 +0,16 +0,49%
Brunel 8,940 +0,04 +0,45%
AMX 889,66 +3,58 +0,40%
ASCX 1.189,51 +4,25 +0,36%
Pharming 0,684 +0,00 +0,29%
TKH 36,720 +0,08 +0,22%
Ahold Delhaize 31,260 +0,06 +0,19%
BAM 3,690 +0,01 +0,16%
Fagron 19,100 +0,02 +0,10%
Alfen N.V. 13,225 +0,00 +0,04%
ACOMO 17,420 0,00 0,00%

Dalers

instrument koers absoluut verschil relatief verschil
BESI 106,950 -3,85 -3,47%
RELX 41,220 -0,96 -2,28%
INPOST 16,060 -0,36 -2,19%
SBM Offshore 16,140 -0,36 -2,18%
UMG 22,840 -0,49 -2,10%
NX FILTRATION 4,770 -0,10 -2,05%
Wolters Kluwer 150,500 -3,00 -1,95%
ASML 722,800 -13,60 -1,85%
Fugro 20,880 -0,38 -1,79%
ADYEN NV 1.268,400 -22,80 -1,77%
Avantium 1,798 -0,03 -1,75%
ASMI 545,800 -9,60 -1,73%
HEIJMANS KON 24,150 -0,40 -1,63%
Vastned 24,250 -0,30 -1,22%
IMCD 149,950 -1,50 -0,99%
THEON INTERNAT 10,560 -0,08 -0,75%
Arcadis 64,250 -0,40 -0,62%
AEX 892,44 -4,54 -0,51%
DSM FIRMENICH AG 119,550 -0,60 -0,50%
OCI 28,740 -0,14 -0,48%
AALBERTS NV 34,580 -0,14 -0,40%
RENEWI 7,690 -0,03 -0,39%
Galapagos 25,760 -0,10 -0,39%
Nedap N.V. 57,000 -0,20 -0,35%
EXOR NV 98,750 -0,25 -0,25%
UNILEVER PLC 58,740 -0,12 -0,20%
Sligro 12,760 -0,02 -0,16%
SHELL PLC 30,990 -0,02 -0,05%
vlag naam koers verschil relatief verschil
AEX 892,27 -4,71 -0,53%
AEX GR 3.488,22 -16,91 -0,48%
Germany40^ 18.622,00 +30,15 +0,16%
FTSE 100 8.259,70 -9,90 -0,12%
EURO50 4.828,09 -15,15 -0,31%
US30^ 40.993,30 +42,60 +0,10%
Nasd100^ 18.894,10 -25,20 -0,13%
US500^ 5.520,27 +3,31 +0,06%
Japan225^ 36.765,00 +42,70 +0,12%
VD-NEW 17,66 +1,45 +8,97%
#/^ Index indications calculated real time, zie disclaimer